Organization
Sichuan Cancer Hospital & Institute, Sichuan
7 abstracts
Abstract
Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.Org: Shanxi Provincial People’s Hospital, Xi'an, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sichuan Cancer Hospital & Institute, Sichuan, Cancer Center, Chengdu, China,
Abstract
Study on the mechanism of ginsenoside Rg5 attenuating radiation myocarditis through GDF11-SIRT1 pathway.Org: Sichuan Cancer Hospital & Institute, Sichuan, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Chengdu, China, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China,
Abstract
A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Anyang Tumor Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, School of Medicine, Zhejiang University, Hangzhou, China, University of Electronic Science and Technology of China,
Abstract
Exploring the most appropriate primary endpoint of immune checkpoint inhibitors for previously treated advanced solid cancers.Org: Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institute, Sichuan, West China Hospital of Sichuan University, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: A retrospective study.Org: Sichuan Cancer Hospital & Institute, Sichuan, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, School of Medicine, Zhejiang University, Hangzhou, China, University of Electronic Science and Technology of China,
Abstract
Surgical outcomes and patient-reported outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy.Org: Sichuan Cancer Hospital & Institute, Sichuan, Southwest Medical University, Thocacic Surgery Department, Sichuan Cancer hospital institute, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China,